RxDoctor Payments Data

Shanmugam Uthamalingam, MD

Cardiovascular Disease · Kingwood, TXNPI 1629039904

Payments from drug & device makers

$6,595in general payments, 2019–2025

Across 234 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$1K
  • Novartis$1K
  • Boston Scientific$787
  • Amgen$553
  • Abbott$439
  • E.r. Squibb & Sons, L.L.C.$332
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$98915%
  • Food & beverage$5,56784%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,595 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$290,626
Medicare patients
526
Services billed
2,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$198,369
Repatha SureclickEvolocumab107$78,423
EntrestoSacubitril/Valsartan53$72,724
XareltoRivaroxaban49$36,940
BrilintaTicagrelor45$30,258
JardianceEmpagliflozin18$15,548
VascepaIcosapent Ethyl23$11,315
Praluent PenAlirocumab12$8,449
Repatha SyringeEvolocumab11$5,877
Ranolazine ErRanolazine22$3,376
Metoprolol Succinate360$3,194
Flecainide Acetate123$3,055
Potassium Chloride138$2,476
Rosuvastatin Calcium184$2,354
Midodrine Hcl37$2,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$198,369200 claims
NovartisEntresto$1,008$72,72453 claims
Johnson & JohnsonXarelto$284$36,94049 claims
AstraZenecaBrilinta$192$30,25845 claims
Boehringer IngelheimJardiance$111$15,54818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →